Introduction {#Sec1}
============

Ventricular dysfunction and circulatory failure with progressing end-organ impairment like renal or liver dysfunction are an important cause of morbidity and mortality in adults with complex congenital heart disease (CHD), especially in patients with single-ventricle types of CHD and Fontan circulation^[@CR1],[@CR2]^. Besides limited cardiac output, alterations that mark Fontan hemodynamics are passive flow to the lungs, chronically elevated venous pressures, and congestion. Unfortunately, the clinical use of traditional markers such as N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels for non-invasive diagnostics and monitoring in such patients is limited^[@CR3],[@CR4]^. Thus, for early detection of cardiac and circulatory derangement and for evaluation and tailoring of treatment options, regular functional assessment of these patients is crucial, with complete clinical examination, electrocardiogram, imaging studies, determination of values for traditional laboratory markers, or exercise capacity testing. In adult biventricular patients, novel candidate biomarkers, in addition to natriuretic peptides and troponins, for congestive heart failure and vascular perturbations have been identified via metabolomics, the study of small organic molecules, their synthesis, and their breakdown^[@CR5],[@CR6]^. Interest has grown recently in the metabolic status of Fontan patients: besides reported abnormalities in Fontan patients' glucose metabolism^[@CR7]^, to date their handling of lipids has been best studied, with important changes shown, especially in the cholesterol, lipoprotein, and phospholipid pathways, hinting at chronic low-level inflammation and at altered cell signalling and energy metabolism as are found in biventricular patients with congestive heart failure^[@CR8],[@CR9]^. In the biventricular patient with heart failure, alterations occur especially in the handling of amino acids important in both myocardium protein turnover and energy metabolism^[@CR10]^. Additionally, the Fontan-specific characteristic of chronically elevated venous pressure favors development of a protein losing enteropathy together with end-organ, especially liver, dysfunction^[@CR2]^. Thus, study of the metabolism of amino acids also should be a promising field in Fontan patients. With the help of targeted metabolomic examinations we hence elected to investigate amino acid metabolism in a homogeneous adult Fontan-patient group with a dominant left ventricle, seeking biomarker patterns that might permit a better understanding of Fontan pathophysiology or early detection of ventricular or circulatory dysfunction.

Results {#Sec2}
=======

After applying all inclusion and exclusion criteria, 20 adult Fontan patients with a systemic left ventricle were selected for the study (Supplemental Fig. [1](#MOESM1){ref-type="media"}). The results of "traditional" examinations (patient and control clinical assessment, exercise capacity testing, routine laboratory analyses) are set out in our recent work on lipid metabolism^[@CR9]^. Table [1](#Tab1){ref-type="table"} lists clinical and exercise capacity testing parameters, showing as major features that in Fontan patients, minimum (at exercise) and maximum (at rest) pulse-oximeter oxygen saturation as well as $\documentclass[12pt]{minimal}
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Routine analytes {#Sec3}
----------------

Hematocrit, hemoglobin concentrations ("hemoglobin"), gamma glutamyl transferase and alanine aminotransferase activities, total bilirubin and creatinine concentrations ("total bilirubin" and "creatinine"), and international normalized ratio (INR) values and triglyceride and high density lipoprotein-cholesterol (HDL-C) concentrations ("triglycerides" and "HDL-C") differed significantly between Fontan patients and controls (Table [2](#Tab2){ref-type="table"}).Table 2Values of routine analytes and of amino acids or biogenic amines and their derivatives.Fontan patientsControlsP-valueHematocrit \[%\]47.8 ± 5.639.3 ± 4.2\<0.00001↑Hemoglobin \[g/dL\]16.4 ± 2.112.7 ± 1.4\<0.00001↑Total cholesterol \[mg/dL\]145.3 ± 26.5149 ± 34.20.77HDL-C \[mg/dL\]42.5 ± 15.951.3 ± 12.30.03↓Non-HDL-C \[mg/dL\]85.2 ± 24.873.1 ± 20.80.2Triglycerides \[mg/dL\]128.6 ± 86.547.3 ± 22.80.003↑Total protein \[g/dL\]7.2 ± 0.57.0 ± 0.70.31Albumin \[mg/dL\]4145 ± 4924215 ± 2080.64Creatinine \[mg/dL\]0.8 ± 0.120.53 ± 0.18\<0.00001↑Total bilirubin \[mg/dL\]1.22 ± 0.670.3 ± 0.29\<0.00001↑AST \[U/L\]35.3 ± 7.731.6 ± 8.40.12ALT \[U/L\]39.4 ± 11.431.9 ± 10.10.04↑gGT \[U/L\]86.5 ± 43.635.1 ± 19.40.00002↑INR2.1 ± 0.761.02 ± 0.04\<0.00001↑NT-proBNP \[pg/mL\]52.4 ± 69.239.3 ± 30.40.88CRP \[mg/dL\]0.18 ± 0.20.16 ± 0.140.47Values are given as mean ± standard deviation. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; dL, decilitre; g, gram; gGT, gamma glutamyl transferase; HDL-C, high density lipoprotein-cholesterol; INR, international normalized ratio; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; U, unit; ↑, statistically significant higher serum concentration in Fontan patients than in controls; ↓, statistically significant lower serum concentration in Fontan patients than in controls.

Metabolomic examination of serum amino acids {#Sec4}
--------------------------------------------

Serum concentrations of 29 amino acids or biogenic amines and their derivatives were determined, with selected sums and ratios (Table [3](#Tab3){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}). In Fontan patients serum concentrations of methionine (Met) sulfoxide (Met-SO), asymmetric dimethyl arginine (ADMA), glutamic acid, and trans-4-hydroxyproline and the ratio of Met-SO to Met (Met-SO/Met) were significantly higher, and serum concentrations of asparagine, histidine, taurine, and threonine were significantly lower than in controls.Table 3Values of amino acids or biogenic amines and their derivatives, and of selected sums and ratios.MetaboliteHMBD IDPatientsControlsp-valueq-valuemean FCAc-OrnHMDB0003357NANANANANAADMAHMDB015390.51 ± 0.120.41 ± 0.050.00040.002↑1.26AlanineHMDB00161 HMDB01310401.4 ± 84.2410.5 ± 123.00.990.99−1.02alpha-AAAHMDB005101.12 ± 0.610.77 ± 0.440.030.061.44ArginineHMDB00517 HMDB0341691.7 ± 26.8108.2 ± 21.80.030.06−1.18AsparagineHMDB00168 HMDB00337843.7 ± 7.750.7 ± 8.00.0070.016↓−1.16Aspartic acidHMDB00191 HMDB0648318.0 ± 10.417.2 ± 6.90.930.961.05c4-OH-ProHMDB0240251NANANANANACarnosineHMDB00033NANANANANACitrullineHMDB0090429.4 ± 6.329.2 ± 6.60.910.951.01DOPAHMDB00181 HMDB00609NANANANANADopamineHMDB00073NANANANANAGlutamineHMDB00641 HMDB03423717.4 ± 134.1749.0 ± 111.70.380.47−1.04Glutamic acidHMDB00148 HMDB0333985.9 ± 63.447.0 ± 21.80.00060.002↑1.83GlycineHMDB00123321.6 ± 74.1345.3 ± 91.70.410.5−1.07HistidineHMDB0017793.1 ± 15110.4 ± 24.40.0080.02↓−1.19HistamineHMDB00870NANANANANAIsoleucineHMDB00172 HMDB0000557106.6 ± 31.6100.9 ± 39.50.440.531.06KynurenineHMDB00684NANANANANALeucineHMDB00687 HMDB0013773222.9 ± 78.6232.8 ± 106.60.990.99−1.04LysineHMDB00182 HMDB03405168.1 ± 23.5165.8 ± 32.40.690.791.01MethionineHMDB0069627.9 ± 8.329.4 ± 7.80.470.55−1.06Met-SOHMDB020050.94 ± 0.320.58 ± 0.230.000080.0005↑1.64Nitro-TyrHMDB01904NANANANANAOrnithineHMDB00214 HMDB03374139.4 ± 82.3111.6 ± 40.90.220.291.25PEAHMDB0012275NANANANANAPhenylalanineHMDB0015977.7 ± 16.977.0 ± 12.90.990.991.01ProlineHMDB00162 HMDB03411259.4 ± 63.7265.7 ± 61.60.730.81−1.02PutrescineHMDB01414NANANANANASarcosineHMDB002711.57 ± 0.941.62 ± 0.790.730.81−1.03SDMAHMDB033340.46 ± 0.060.42 ± 0.080.10.151.08SerineHMDB00187 HMDB03406158.4 ± 33.3146.5 ± 23.70.210.291.08SerotoninHMDB002590.56 ± 0.330.7 ± 0.210.030.06−1.26SpermidineHMDB01257NANANANANASpermineHMDB01256NANANANANAt4-OH-ProHMDB00725 HMDB000605515.8 ± 5.0611.7 ± 5.20.0070.02↑1.35TaurineHMDB00251100.4 ± 57.1132.6 ± 56.540.020.049↓−1.32ThreonineHMDB04041 HMDB00167105.6 ± 21.0127.3 ± 28.40.0080.02↓−1.21TryptophanHMDB00929 HMDB001360990.5 ± 20.289.5 ± 23.30.840.891.01TyrosineHMDB0015887.0 ± 23.083.6 ± 19.40.690.791.04ValineHMDB00883298.9 ± 72.5290.7 ± 76.90.70.791.03BCAA628 ± 174624 ± 2170.80.871.01AAA255 ± 53250 ± 470.80.871.02Total AA3544 ± 4663588 ± 6820.930.96−1.01Essential AA1098 ± 2231113 ± 2930.970.99−1.01Fischer ratio2.47 ± 0.522.45 ± 0.50.90.951.01Met-SO/Met0.04 ± 0.0160.02 ± 0.007\<0.000010.0001↑1.78Metabolite concentrations for all analytes with selected sums and ratios, grouped by Fontan patients vs. controls. Values are given as mean ± standard deviation, unit of values of data \[µmol/l\]. FC, fold change (Fontan patients vs. controls); HMBD ID, Human Metabolome Database identification; AA, amino acids; AAA, aromatic amino acids; Ac-Orn, acetylornithine; ADMA, asymmetric dimethylarginine; alpha-AAA, alpha aminoadipic acid; BCAA, branched-chain amino acids; c4-OH-Pro, cis-4-hydroxyproline; DOPA, dihydroxyphenylalanine; Met-SO, methionine sulfoxide; Nitro-Tyr, nitrotyrosine; PEA, phenylethylamine; SDMA, symmetric dimethylarginine; t4-OH-Pro, trans-4-hydroxyproline; ↑, statistically significant higher serum concentration in Fontan patients than in controls; ↓, statistically significant lower serum concentration in Fontan patients than in controls. 'Fischer ratio' is the ratio of BCAA/AAA.Figure 1Box-and-whisker plots of serum concentrations of amino acids or biogenic amines and their ratios that differed significantly between Fontan patients (grey boxes) and controls (white boxes). The boxes show the 1^st^ (Q1) and 3^rd^ quartile (Q3), the whiskers the minimum and the maximum. Black circles represent outlying values as identified by the interquartile range (IQR) rule (values smaller than (Q1-1.5\*IQR) or values larger than (Q3 + 1.5\*IQR)). ADMA, asymmetric dimethylarginine; Asn, asparagine; Glu, glutamic acid; His, histidine; Met, methionine; Met-SO, methionine sulfoxide; Met-SO/Met, methionine sulfoxide/methionine ratio; t4-OH-Pro, trans-4-hydroxyproline; Tau, taurine; Thr, threonine.

Correlation of routine biochemical and clinical findings with metabolomic parameters {#Sec5}
------------------------------------------------------------------------------------

Among routine analytes, the variables hemoglobin, albumin, and triglycerides displayed significantly positive correlations with glutamic acid. Creatinine and triglycerides displayed significantly positive correlations with ADMA, as did the variables creatinine and total bilirubin with Met-SO. Hematocrit, hemoglobin, and INR as well as minimum and maximum oxygen saturations revealed significantly positive correlations with Met-SO/Met values, and oxygen uptake at the anaerobic threshold and maximum oxygen uptake displayed significantly negative correlations with Met-SO/Met values. Single significant correlations between isolated variables included positive correlation of albumin with ornithine and serine, of triglycerides with alpha aminoadipic acid, and of the oxygen uptake at the anaerobic threshold with threonine as well as negative correlations of alanine aminotransferase activity with taurine and of INR with serotonin. No further correlations were identified, especially none with CRP or NT-proBNP (Supplemental Table [1](#MOESM2){ref-type="media"}).

Discussion {#Sec6}
==========

To the best of our knowledge, our study is the first clinical metabolomics study focusing on Fontan patients' serum amino acid patterns. Its main finding is that, in comparison with controls, adult Fontan patients with a morphologically left dominant ventricle exhibit a distorted amino acid metabolome, hinting at altered (myocardial) cell energy metabolism and an elevated myocardial protein turnover as well as at oxidative stress and endothelial dysfunction, as found in biventricular patients with congestive heart failure.

Altered cell energy metabolism and elevated myocardial protein turnover {#Sec7}
-----------------------------------------------------------------------

Decreased serum concentrations of taurine, asparagine, and threonine and increased concentrations of glutamic acid and hydroxyproline in our Fontan patients indicate alterations in (myocardial) cell energy metabolism and elevated myocardium protein turnover, as found in biventricular patients with congestive heart failure. Taurine is abundant in myocardial tissue, with a major function in regulation of the respiratory chain: the taurine-deficient heart suffers impaired respiratory chain function and diminished long chain fatty acid uptake by mitochondria, as found in patients with congestive heart failure^[@CR10]^. Decreased concentrations of taurine are described in patients with dilated cardiomyopathy and in golden retrievers with heart failure^[@CR10],[@CR11]^, and many studies report a beneficial effect of taurine supplementation on myocardial function in patients with congestive heart failure^[@CR12]^.

Glutamic acid and asparagine also take part in central pathways of aerobic cell respiration and thereby of energy production. Via anaplerotic reactions, both amino acids are substantially involved in the tricarboxylic acid cycle^[@CR13]^. Against the background of a switch in heart failure of preferred myocardial energy substrate from fatty acids to glucose and ketone bodies^[@CR14]^, our findings hint at altered myocardial energy metabolism, indicating subtle ventricular dysfunction. This idea is supported by glutamic acid's involvement in the synthesis of metabolites, *e.g*., by serving as a precursor for the biosynthesis of amino acids such as proline and arginine^[@CR15],[@CR16]^. Indeed, increased serum levels of glutamic acid indicate increased protein turnover, as typical in adults with congestive heart failure or coronary heart disease^[@CR17],[@CR18]^. The same is true for threonine, a major component of proteins, *e.g*., of collagen and immunoglobulins: We found decreased serum threonine levels, and decreased plasma levels are described in patients with chronic heart failure^[@CR17]^. The increase that we observed in hydroxyproline, an analyte used to track collagen degradation, also reflects elevated protein turnover: Elevated urine and serum hydroxyproline levels are reported after muscle damage or in the bedridden and elderly^[@CR19],[@CR20]^.

Oxidative stress and endothelial dysfunction {#Sec8}
--------------------------------------------

Protein turnover also is elevated in  the presence of hyperreactive oxygen species, *i.e*., under oxidative stress and during endothelial dysfunction, both of which are directly linked to heart failure: Nitrous oxide (NO) synthase (NOS) isoforms are expressed not only in endothelial cells but also in cardiomyocytes, and NO regulates cardiac function through vascular-dependent and -independent effects, with, in the healthy heart, a positive inotropic effect at low NO exposure and a negative one at higher exposure^[@CR21],[@CR22]^. In heart failure, regulation of myocardial NO production and release breaks down, with excessive release, and peripheral and vascular endothelial NOS activity is lost, resulting in endothelial dysfunction with decreased NO bioavailability attributable to increased oxidative stress^[@CR23]^. In the course of cardiac decompensation, NO likely influences several of the core features of cardiac failure, *e.g*., chamber dilation, defective b-adrenergic responsiveness, and calcium cycling^[@CR22]^.

That serum concentrations of ADMA were elevated also suggests that our Fontan patients were under oxidative stress, with altered endothelial function, consistent with subtle ventricular dysfunction. ADMA, a methyl derivate of arginine, is involved in NO-signalling and in pro- and antioxidant and -inflammatory processes. It is the major endogenous inhibitor of nitric oxide synthase (NOS). By displacing arginine, the normal NOS substrate, ADMA enhances oxidative stress by influencing NO-reactive oxygen species balance and disturbs vasodilation^[@CR21],[@CR24]--[@CR26]^. ADMA values reportedly track enhanced cardiovascular risk with endothelial dysfunction^[@CR27],[@CR28]^, positively correlating with age, mean arterial pressure, renovascular resistance, intimal media thickness, and peripheral arterial occlusive disease^[@CR5],[@CR29]--[@CR33]^, ADMA is additionally involved in further nitric oxide (NO)-dependent signalling processes, interfering with anti-thrombotic, anti-inflammatory, and anti-apoptotic actions^[@CR21]^.

The increases in value for Met-SO and for the Met-SO/Met ratio as indicators of systemic oxidative stress also suggest that our patients are under oxidative stress and suffer from endothelial dysfunction. Reaction with oxygen species yields Met-SO, which activates endogenous antioxidant enzymes such as Met-SO reductase A and induces synthesis of glutathione, thereby counteracting oxidative stress and inflammation^[@CR34]^. Increased Met-SO levels have been reported in vascular disease, cardiac ischemia, and in left ventricular diastolic dysfunction^[@CR35],[@CR36]^. The negative correlation observed between Met-SO/Met values and oxygen uptake under exercise strikingly emphasizes the role of markers of oxidative stress as indicators for subtle ventricular dysfunction in our patients. Finally, our hypothesis that oxidative stress affects our patients is supported by the decreased level found of histidine, with its anti-oxidant and anti-inflammatory properties^[@CR37]^, and by decreases in HDL-C^[@CR9],[@CR38]--[@CR40]^. A direct interplay of lipoprotein metabolism and markers for oxidative stress exists: lipoprotein disorders are associated with increased ADMA^[@CR41]^.

ADMA also has been used to track heart failure in patients with CHD, and with regard to heart failure is even more sensitive than NT-proBNP. However, only 13% of the patients studied had univentricular heart disease; in addition, patient exercise capacity was lower than that in our patient group^[@CR33]^. Thus we stress that our findings of altered amino acid serum levels might imply subtle rather than frank heart failure^[@CR42],[@CR43]^, a hypothesis supported by the fact that we found no correlation of any of the metabolites with the traditional marker for heart failure, NT-proBNP, nor with the traditional marker for inflammation C-reactive protein, and by the fact that neither by traditional clinical-laboratory means nor by metabolomic (Fischer ratio) criteria did we find any evidence for important (Fontan-associated) liver disease in our patients. Given that many adult Fontan patients will develop ventricular dysfunction, to hypothesise subtle heart failure in our patient group might well be appropriate^[@CR1]^. Still, with respect to the definition of heart failure, which is the "inability of the heart to meet resting and exercise demands at low filling pressures"^[@CR2]^, we cannot exclude with certainty that the metabolic alterations delineated solely reflect Fontan-specific pathophysiology with its circulatory abnormalities, with paramount abnormal systemic or pulmonary endothelial function, and with a tendency towards the formation of veno-venous or aortopulmonary collaterals^[@CR44]--[@CR48]^.

To examine the amino acid profile of Fontan patients with frank ventricular, circulatory, or hepatic impairment and to correlate increases in serum ADMA and Met-SO content with direct measurement of endothelin or with collateral vessel flow via magnetic resonance imaging studies thus would be of interest^[@CR49],[@CR50]^.

Limitations {#Sec9}
-----------

Because Fontan patients are few, the studied group size is small, possibly limiting the extent to which our findings can be generalized. Also limiting may be our choice of a targeted metabolomic approach and a commercial kit, as metabolites not assessed may be important. That we analyzed serum samples precludes direct comparison between our results and those of studies that used tissue samples, and we acknowledge that having assayed serum rather than vascular or myocardial tissue, we cannot rule out certain system-driven aspects of disease pathogenesis: That is, unknown confounders that affect metabolic profiles might be the true basis for the observed differences. Moreover, differences in body composition or lifestyle parameters might have influenced our results to an unknown degree. We strove to lessen the likelihood of such errors by following a strict inclusion and exclusion protocol, especially with regard to (known) comorbidities or medication.

Conclusion {#Sec10}
==========

The striking alterations in amino acid profile that we found may link Fontan pathophysiology with altered cell energy metabolism, oxidative stress, and endothelial dysfunction as found in biventricular patients with congestive heart failure. Markers identified through mass spectrometry-based extended amino acid metabolism might thus complement traditional diagnostic tools such as imaging, exercise capacity testing, and traditional laboratory biomarker determinations, yielding a better understanding of Fontan pathophysiology, and they are promising candidates for the early detection of ventricular or circulatory dysfunction in Fontan patients.

Methods {#Sec11}
=======

Like our recently published results on phospholipid and acylcarnitine metabolomic examinations, this work is a subwork of the main study protocol (Trial registration number: ClinicalTrials.gov Identifier NCT03886935)^[@CR9]^.

Patients {#Sec12}
--------

Between September 2016 and March 2017, we prospectively examined adult Fontan patients with a dominant left single ventricle and age- and sex-matched healthy biventricular controls at the Center of Pediatric Cardiology and Congenital Heart Disease, Heart and Diabetes Center North Rhine-Westphalia, Ruhr-University of Bochum, Germany^[@CR9]^. All patients had undergone two-stage palliation with partial and total cavopulmonary anastomosis. None had had aortic reconstruction or aortopulmonary shunting. Table [4](#Tab4){ref-type="table"} shows inclusion and exclusion criteria. See the flow chart according to STROBE (Strengthening the Reporting of Observational Studies in Epidemiology \[<https://strobe-statement.org/index.php?id=strobe-home>\]) (Supplemental Fig. [1](#MOESM1){ref-type="media"}) for details on the flow of patients through the present study.Table 4Inclusion and exclusion criteria^[@CR9]^.Inclusion criteriaExclusion criteriaWritten informed consentMedication affecting metabolic stateAge ≥18 yearsMedication affecting hemodynamic state8 hours fasting before blood samplingCoronary artery diseaseDominant left ventricle (patients)Failure of systemic ventricleBiventricular healthy heart (controls)Valvular stenosisAtrioventricular regurgitation \> mildAortic regurgitation \> mildRecurrent effusionsProtein-losing enteropathyMetabolic diseaseMalignancyOther cachectic disease, malnutritionInflammatory diseaseMyeloproliferative disorderPregnancy or lactationMultiple organ failureMental or physical handicap precluding exercise$\documentclass[12pt]{minimal}
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Clinical and laboratory examinations were performed as described in detail elsewhere^[@CR9]^. Age, sex, weight, medication, and cardiac risk factor assessment, with blood sampling for routine hematological and biochemical profiling, was conducted during an outpatient visit. Fasting patients underwent phlebotomy while recumbent. Echocardiography followed, and, after a defined snack rich in carbohydrates, exercise capacity was tested. We correlated metabolic results with routine laboratory parameters and exercise capacity parameters^[@CR51]^. All patients underwent symptom-limited treadmill exercise capacity testing with expiratory gas analysis^[@CR52]^. A 12-lead ECG was used to determine heart rate. Oxygen uptake at rest ($\documentclass[12pt]{minimal}
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Blood studies required samples 0.5 ml greater than those for routine assessments to permit determinations of concentrations of amino acid-metabolism analytes. The blood sample was directly drawn into a tube containing a clotting activator and centrifuged within 20 min (15 °C, 10 min, 2500 × g) for separation of serum. Serum aliquots were immediately frozen and stored at -80 °C for further analyses. Frozen samples were transported on dry ice to the analysing laboratory. Analyses were performed in batches of 10 samples^[@CR9]^.

Sample preparation {#Sec13}
------------------

Before analysis, all serum samples were processed as described, with samples thawed on ice, then centrifuged; the supernatant was subjected to further analyses^[@CR6],[@CR9]^. The AbsoluteIDQ p180 kit assay (Biocrates Life Sciences AG, Innsbruck, Austria) permitted targeted, fully automated quantification of 188 analytes (42 amino acids or biogenic amines and their derivatives) based on phenylisothiocyanate derivatization in the presence of internal standards followed by liquid chromatography mass spectrometry using a TSQ-Vantage (Thermo Fisher Scientific, Waltham, MA) instrument with electrospray ionization.

Statistical analysis {#Sec14}
--------------------

To exclude metabolites below the limit of detection (LOD), the raw data (µmol/L) were cleaned applying a modified 80% rule; for statistical analysis at least 80% valid values above LOD needed to be available per analyte in the samples for each group. This reduced the dataset to 143 analytes (29 amino acids or biogenic amines and their derivatives). Remaining values below LOD were imputed applying a logspline method with values between LOD and LOD/2. After log2 transformation of metabolomics data as well as of routine analytes and clinical data the dataset underwent multivariate (hierarchical cluster analysis) and univariate statistical analyses. Student's t-testing with a Benjamini-Hochberg correction identified significant metabolite (and clinical routine-parameter) differences between patients and controls. P-values were calculated to identify significant changes between controls and Fontan patients, and were adjusted for multiple testing, or false discovery rate (FDR), according to Benjamini and Hochberg. To interpret the correlation, the significance of the correlation was calculated from r and from the degrees of freedom (a variable dependent on the sample number) (Supplemental Table [1](#MOESM2){ref-type="media"}). As a measure of linear correlation, r can have values between −1 and 1, where 1 indicates total positive linear correlation, 0 indicates no linear correlation, and −1 indicates total negative linear correlation. Correlations with FDR-adjusted p-values \<0.05 and r \> 0.5 (\<−0.5) were considered statistically significant; in Supplemental Table [1](#MOESM2){ref-type="media"}, table cells displaying a statistically significant correlation are highlighted by a green background^[@CR9]^.

Ethical approval and informed consent {#Sec15}
-------------------------------------
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